Genocea Biosciences (GNCA) Misses Q4 EPS by 11c

Genocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.56), $0.11 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $0, versus $0 reported last year.

Cash, cash equivalents and investments as of December 31, 2016 were $63.4 million compared to $75.5 million as of September 30, 2016.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Science Applications (SAIC) PT Raised to $154 at Stifel
• Ascendis Pharma (ASND) PT Lowered to $304 at BofA Securities